The Consultation That Changed How I Practice GYN
Lorem ipsum dolor sit amet, consectetur adipiscing. A case that forced a rethink of how I approach midlife care — and why I still use it as a teaching case today.
What the 2023 NAMS Guidelines Actually Changed
In September 2023, the North American Menopause Society released an updated position statement on hormone therapy — the most substantive revision to their guidance in nearly a decade. The clinical community largely noticed the headline: a softening of age-based restrictions. What got less attention were the specific mechanism changes, the new framing of cardiovascular risk, and the updated language on duration of therapy. This article breaks down what actually changed and what it means for clinical practice today.
What the 2023 Position Statement Actually Said
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. The 2023 statement formally retired the concept of a strict ten-year "window" for initiating therapy, replacing it with a more nuanced risk-stratification framework that weighs age at menopause onset, time since last menstrual period, and individual cardiovascular and bone risk profiles.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Perhaps most significantly, the statement explicitly acknowledged that the Women's Health Initiative findings had been over-applied to populations for whom the data was never intended — namely, healthy women in early menopause presenting with significant vasomotor symptoms.
"For healthy, symptomatic women under 60 and within ten years of menopause onset, the benefit-risk ratio for hormone therapy is favorable in most cases."
— NAMS 2023 Position Statement
Clinical Implications for Practice
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. For most clinicians seeing patients in their late forties and early fifties, the updated guidance reinforces what many have already concluded from clinical experience: the prior hesitancy around hormone therapy was frequently disproportionate to the actual risk profile of the patient in front of them.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. In practice, the 2023 updates most directly affect three patient types:
- Women presenting with moderate to severe vasomotor symptoms who were previously declined therapy due to age alone
- Women with premature ovarian insufficiency or surgical menopause, for whom the ten-year framing was always clinically inappropriate
- Women seeking extended therapy who had been advised to discontinue at the five-year mark without individualized assessment
What Hasn't Changed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. The contraindications remain substantively the same: unexplained vaginal bleeding, active or recent hormone-sensitive cancer, active thromboembolic disease, and uncontrolled cardiovascular disease. The update does not greenlight hormone therapy across the board — it narrows the lens of appropriate caution.
A Note on Shared Decision-Making
Lorem ipsum dolor sit amet, consectetur adipiscing elit. The updated statement spends considerable space on the communication framework — specifically, how to present benefit-risk tradeoffs to patients who arrive with misconceptions shaped by the WHI headlines of the early 2000s. For many patients, the framing question isn't whether hormone therapy is an option; it's whether their provider will take the conversation seriously.
Clinical Note
The module on shared decision-making in Menopause: by Midwives covers scripted language for this exact conversation — including how to address the WHI directly with patients who cite it as their primary concern.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium. In practice, the clinicians who navigate this most effectively are the ones who can give patients a coherent, confident two-minute summary of what the evidence actually says — not what a news article said it said twenty years ago. That's a communication skill, not just a knowledge gap, and it requires deliberate practice.
